This study is currently recruiting participants.
Verified November 2012 by Opexa Therapeutics, Inc.
Study Purpose:
The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell Immunotherapy) is effective in the treatment of secondary progressive multiple sclerosis (SPMS).
Investigators in the
United States and Canada are recruiting 180 people with secondary-progressive
MS for a study to determine the effectiveness of TcelnaTM (imilecleucel-T,
Opexa Therapeutics) in slowing disease progression in this progressive
population.
United States and Canada are recruiting 180 people with secondary-progressive
MS for a study to determine the effectiveness of TcelnaTM (imilecleucel-T,
Opexa Therapeutics) in slowing disease progression in this progressive
population.
Find out if there is a recruiting in/around your state looking for
your participation:
your participation:
..
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
